These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 21079210)

  • 1. ACP Journal Club. Review: Erythropoiesis-stimulating agents targeted to higher hemoglobin levels increase risk for adverse outcomes in CKD.
    Hsu CY
    Ann Intern Med; 2010 Nov; 153(10):JC5-3. PubMed ID: 21079210
    [No Abstract]   [Full Text] [Related]  

  • 2. ACP Journal Club. Review: Erythropoiesis-stimulating agents increase mortality in patients with cancer.
    Matulonis U
    Ann Intern Med; 2009 Sep; 151(6):JC3-7. PubMed ID: 19755353
    [No Abstract]   [Full Text] [Related]  

  • 3. Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets.
    Fishbane S; Besarab A
    Clin J Am Soc Nephrol; 2007 Nov; 2(6):1274-82. PubMed ID: 17942772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACP Journal Club. Review: Tamoxifen, raloxifene, and tibolone prevent primary invasive breast cancer but increase risk for adverse outcomes.
    Melnikow J
    Ann Intern Med; 2010 Mar; 152(6):JC3-4. PubMed ID: 20231558
    [No Abstract]   [Full Text] [Related]  

  • 5. ACP Journal Club. Review: biologic agents increase short-term risk for some adverse events in conditions other than HIV or AIDS.
    Schattner A
    Ann Intern Med; 2012 May; 156(10):JC5-9. PubMed ID: 22586027
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD.
    Aspinall SL; Cunningham FE; Zhao X; Boresi JS; Tonnu-Mihara IQ; Smith KJ; Stone RA; Good CB;
    Am J Kidney Dis; 2012 Sep; 60(3):371-9. PubMed ID: 22633556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ACP Journal Club. Review: angiotensin-receptor blockers do not increase adverse cardiovascular outcomes.
    Halim SA; Newby LK
    Ann Intern Med; 2011 Aug; 155(4):JC2-2. PubMed ID: 21844535
    [No Abstract]   [Full Text] [Related]  

  • 8. ACP Journal Club. Review: Oral drugs for gestational diabetes do not increase adverse maternal and neonatal outcomes more than insulin.
    Feig D
    Ann Intern Med; 2009 Apr; 150(8):JC4-9. PubMed ID: 19391223
    [No Abstract]   [Full Text] [Related]  

  • 9. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease.
    Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Tonelli M; Garg AX; Pellegrini F; Ravani P; Jardine M; Perkovic V; Graziano G; McGee R; Nicolucci A; Tognoni G; Strippoli GF
    Ann Intern Med; 2010 Jul; 153(1):23-33. PubMed ID: 20439566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoiesis-stimulating agents, hypertension and left ventricular hypertrophy in the chronic kidney disease patient.
    Schmid H; Schiffl H; Lederer SR
    Curr Opin Nephrol Hypertens; 2011 Sep; 20(5):465-70. PubMed ID: 21738032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ACP Journal Club. Antidepressants were associated with increased risk for adverse outcomes in depressed elders.
    Ito K
    Ann Intern Med; 2012 Feb; 156(4):JC2-13. PubMed ID: 22351739
    [No Abstract]   [Full Text] [Related]  

  • 12. ACP Journal Club. Review: lipid-lowering drugs decrease all-cause and cardiac mortality and CV events in CKD.
    Ramesh Prasad GV
    Ann Intern Med; 2012 Nov; 157(10):JC5-5. PubMed ID: 23165681
    [No Abstract]   [Full Text] [Related]  

  • 13. ACP Journal Club. Review: ACE-Is or ARBs reduce adverse CV outcomes regardless of baseline systolic blood pressure.
    Singh V
    Ann Intern Med; 2012 Jul; 157(2):JC2-8. PubMed ID: 22801699
    [No Abstract]   [Full Text] [Related]  

  • 14. ACP Journal Club. Severe hypoglycemia was associated with increased risk for adverse clinical outcomes in type 2 diabetes.
    Grubina R; Smith SA
    Ann Intern Med; 2011 Feb; 154(4):JC2-13. PubMed ID: 21320928
    [No Abstract]   [Full Text] [Related]  

  • 15. ACP Journal Club. Review: statins decrease mortality and major CV events in adults with CKD not receiving dialysis.
    Ramesh Prasad GV
    Ann Intern Med; 2012 Nov; 157(10):JC5-4. PubMed ID: 23165680
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapy with erythropoiesis-stimulating agents and renal and nonrenal outcomes.
    Agarwal AK; Singh AK
    Heart Fail Clin; 2010 Jul; 6(3):323-32. PubMed ID: 20630407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level?
    Singh AK
    Curr Opin Nephrol Hypertens; 2010 Sep; 19(5):420-4. PubMed ID: 20689425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ACP Journal Club. Review: oral phosphodiesterase 4 inhibitors reduce exacerbations but increase adverse events in COPD.
    Ram FS
    Ann Intern Med; 2011 Sep; 155(6):JC3-2. PubMed ID: 21930839
    [No Abstract]   [Full Text] [Related]  

  • 19. ACP Journal Club: review: dipeptidyl peptidase-4 inhibitors do not increase overall adverse events in type 2 diabetes.
    Chatterjee S; Chatterjee S
    Ann Intern Med; 2013 Apr; 158(8):JC8. PubMed ID: 23588773
    [No Abstract]   [Full Text] [Related]  

  • 20. ACP Journal Club: review: varenicline for tobacco cessation does not increase CV serious adverse events.
    Krebs P; Sherman SE
    Ann Intern Med; 2012 Aug; 157(4):JC2-2. PubMed ID: 22910956
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.